Globally, about 40+ key pharma and biotech companies are working in the Autoimmune Hepatitis therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
DelveInsight’s “Autoimmune Hepatitis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Autoimmune Hepatitis Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Autoimmune Hepatitis market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Autoimmune Hepatitis: An Overview
Autoimmune hepatitis (AIH) is a non-contagious, chronic, inflammatory, autoimmune disease in which one’s own immune system attacks healthy, normal liver cells. The cause of liver cell destruction in this disease is unclear but may be related to an imbalance in some of the immune system cells (effector and regulatory). The persistent inflammation within the liver observed in AIH can result in scarring, ultimately leading to cirrhosis, liver failure requiring a liver transplant, and even death.
Corticosteroids such as prednisone, prednisolone, or budesonide are usually used to help suppress the immune system (so the liver is not attacked) and calm down the inflammation in the liver. Prednisone is a common first treatment. It has been used for many years and tends to work for many. Several key companies are actively working in the therapeutics segment to further improve the treatment scenario.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Autoimmune Hepatitis market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Autoimmune Hepatitis market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.
Autoimmune Hepatitis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders.
Autoimmune Hepatitis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Autoimmune Hepatitis market or expected to get launched during the study period. The analysis covers Autoimmune Hepatitis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Autoimmune Hepatitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Latest Developments in the Autoimmune Hepatitis Therapeutics Market
On October 03, 2022, Kezar Life Sciences, Inc. (Nasdaq: KZR) announced that it had received clearance for its Investigational New Drug (IND) application from the U.S. Food and Drug Administration for zetomipzomib. Zetomipzomib is a first-in-class, selective immunoproteasome inhibitor for the treatment of autoimmune hepatitis (AIH).
Learn How Autoimmune Hepatitis Market Will Evolve by 2032 @ https://www.delveinsight.com/sample-request/autoimmune-hepatitis-market
Autoimmune Hepatitis Therapeutics Analysis
There are approx. 40+ key companies which are developing therapies for Autoimmune Hepatitis. Currently, Novartis has its Autoimmune Hepatitis drug candidates in the most advanced stage of clinical development.
Some of the key companies in the Autoimmune Hepatitis Therapeutics Market include
• TaiwanJ Pharmaceuticals
• Hoffmann-La Roche
• Iltoo Pharma
• CytoDyn Inc.
• Parvus Therapeutics
• TRACT Therapeutics
And many more
Autoimmune Hepatitis Drugs Covered in the report include:
• VAY736: Novartis
• JKB-122: TaiwanJ Pharmaceuticals
And many others
Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More –
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Autoimmune Hepatitis Competitive Intelligence Analysis
4. Autoimmune Hepatitis Market Overview at a Glance
5. Autoimmune Hepatitis Disease Background and Overview
6. Autoimmune Hepatitis Patient Journey
7. Autoimmune Hepatitis Epidemiology and Patient Population (In US, EU5, and Japan)
8. Autoimmune Hepatitis Treatment Algorithm, Current Treatment, and Medical Practices
9. Autoimmune Hepatitis Unmet Needs
10. Key Endpoints of Autoimmune Hepatitis Treatment
11. Autoimmune Hepatitis Marketed Products
12. Autoimmune Hepatitis Emerging Drugs and Latest Therapeutic Advances
13. Autoimmune Hepatitis Seven Major Market Analysis
14. Attribute Analysis
15. Autoimmune Hepatitis Market Outlook (In US, EU5, and Japan)
16. Autoimmune Hepatitis Access and Reimbursement Overview
17. KOL Views on the Autoimmune Hepatitis Market
18. Autoimmune Hepatitis Market Drivers
19. Autoimmune Hepatitis Market Barriers
21. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report:
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports By DelveInsight
“Nontuberculous Mycobacterial (NTM) Infections Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Nontuberculous Mycobacterial (NTM) Infections Market size, share, and trends in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States